Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Q-linea AB's Revenue for the
three
months ended in Jun. 2026 was kr1.50 Mil. Q-linea AB's average Accounts Receivable for the
three
months ended in Jun. 2026 was kr3.06 Mil.
Hence, Q-linea AB's Receivables Turnover for the
three
months ended in Jun. 2026 was 0.49.
Q-linea AB (FRA:3F80) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Q-linea AB Receivables Turnover Related Terms
Q-linea AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Q-linea AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3F80 vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Q-linea AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Q-linea AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-linea AB (FRA:3F80) has a Receivables Turnover of 0.49 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Q-linea AB and its competitors. According to the industry distribution chart, Q-linea AB ranks #716 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 88.3%.
Is Q-linea AB's Receivables Turnover too high?
Q-linea AB's current Receivables Turnover is 0.49. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Q-linea AB's value of 0.49 is 91.1% below this industry median. Based on the distribution chart, Q-linea AB ranks #716 out of 811 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Q-linea AB has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-linea AB ranks #716 out of 811 companies for Receivables Turnover. This places Q-linea AB in the lower half of its industry. The industry median Receivables Turnover is 5.51. Q-linea AB's value of 0.49 is 91.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-linea AB's current Receivables Turnover of 0.49 is 91.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Q-linea AB and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-linea AB's current Receivables Turnover is 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (FRA:3F80) has a current Receivables Turnover of 0.49. The stock's GF Value™ is kr1.76, compared to a current price of kr1.46 — trading 17% below its estimated fair value. The current Receivables Turnover is 0.49 and 91.1% below the Medical Devices & Instruments industry median of 5.51. Q-linea AB's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Q-linea AB (FRA:3F80), the current Receivables Turnover is 0.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (FRA:3F80) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1.46 is trading 17% below its estimated GF Value™ of kr1.76.
Key valuation signals for FRA:3F80:
Receivables Turnover: 0.49
GF Value™: kr1.76 vs. price of kr1.46 (17% below fair value)
Industry Position: 91.1% below the Medical Devices & Instruments median (#716 of 811)
No single metric tells the full story. See the FRA:3F80 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
64GF Score
Get the complete analysis for FRA:3F80
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3F80 has been successfully added to your 
